| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0169-409X(98)00008-8 |
| P698 | PubMed publication ID | 10837646 |
| P2093 | author name string | Singh M | |
| Gupta RK | |||
| O'Hagan DT | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 225-246 | |
| P577 | publication date | 1998-07-01 | |
| P1433 | published in | Advanced Drug Delivery Reviews | Q2825362 |
| P1476 | title | Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines | |
| P478 | volume | 32 |
| Q37384743 | A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis |
| Q80351101 | A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine |
| Q36011349 | A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice |
| Q43534761 | A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine |
| Q56794150 | A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems |
| Q36496104 | A review of CpGs and their relevance to aquaculture |
| Q28752179 | A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1 |
| Q48030185 | A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine |
| Q78673529 | A two-component modular approach for enhancing T-cell activation utilizing a unique anti-FcgammaRI-streptavidin construct and microspheres coated with biotinylated-antigen |
| Q40223307 | Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®. |
| Q79164480 | Adjuvant and immunogenic activities of the 73kDa N-terminal alpha-domain of BrkA autotransporter and Cpn60/60kDa chaperonin of Bordetella pertussis |
| Q34329446 | Adjuvant effect of docetaxel on the immune responses to influenza A H1N1 vaccine in mice |
| Q58827811 | Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection |
| Q38049900 | Adjuvants and inactivated polio vaccine: a systematic review |
| Q35886450 | Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination |
| Q38520210 | Adjuvants in micro- to nanoscale: current state and future direction |
| Q37390078 | Advances in saponin-based adjuvants |
| Q33764666 | Advances in vaccine adjuvants |
| Q38113269 | Allergen-specific immunotherapy in asthmatic children: from the basis to clinical applications |
| Q30368742 | Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. |
| Q81299406 | Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey |
| Q45043926 | Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells |
| Q35739608 | Aluminum as a toxicant |
| Q34990010 | Aluminum hydroxide adjuvant differentially activates the three complement pathways with major involvement of the alternative pathway |
| Q40485597 | An inflammatory response is essential for the development of adaptive immunity-immunogenicity and immunotoxicity |
| Q43883594 | Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity |
| Q33972302 | Antigen delivery by lipid-enveloped PLGA microparticle vaccines mediated by in situ vesicle shedding. |
| Q30360768 | Antigen sparing and enhanced protection using a novel rOv-ASP-1 adjuvant in aqueous formulation with influenza vaccines. |
| Q51994899 | Archaeosomes as adjuvants for combination vaccines. |
| Q39976251 | Automated Gravimetric Calibration to Optimize the Accuracy and Precision of TECAN Freedom EVO Liquid Handler |
| Q36978486 | Biodegradable polylactide microspheres enhance specific immune response induced by Hepatitis B surface antigen. |
| Q28087409 | Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases |
| Q39773773 | Biodegradable thermosensitive injectable PEG-PCL-PEG hydrogel for bFGF antigen delivery to improve humoral immunity |
| Q34345012 | Biomaterials for nanoparticle vaccine delivery systems |
| Q47967491 | Breaking the non-responsiveness of C57BL/6 mice to the malarial antigen EB200--the role of carrier and adjuvant molecules |
| Q28741710 | CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets |
| Q38969062 | Calcium phosphate: a substitute for aluminum adjuvants? |
| Q35219026 | Cancer vaccines: between the idea and the reality |
| Q37377608 | Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine |
| Q38587300 | Carbohydrate-based vaccine adjuvants - discovery and development |
| Q42220713 | Co-administration of non-carrier nanoparticles boosts antigen immune response without requiring protein conjugation. |
| Q82634234 | Codelivery of adjuvants at the primary immunization site is essential for evoking a robust immune response to neoglycoconjugates |
| Q36191001 | Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs |
| Q82227312 | Comparative study of the effects of aluminum adjuvants and Freund's incomplete adjuvant on the immune response to an Edwardsiella tarda major antigen |
| Q57349484 | Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery |
| Q39869935 | Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides |
| Q37007729 | Controlled release behaviour of protein-loaded microparticles prepared via coaxial or emulsion electrospray |
| Q47841368 | CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle |
| Q52945881 | CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. |
| Q35953768 | Cytokines as adjuvants for avian vaccines |
| Q34280941 | Defined synthetic vaccines |
| Q33733590 | Delivery of foreign antigens by engineered outer membrane vesicle vaccines |
| Q36640326 | Delivery systems and adjuvants for oral vaccines. |
| Q37062606 | Design opportunities for actively targeted nanoparticle vaccines |
| Q37808118 | Designing polymeric particles for antigen delivery |
| Q40694023 | Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles. |
| Q57260495 | Development of candidate combination vaccine for hepatitis E and hepatitis B: A liposome encapsulation approach |
| Q35918800 | Development of safe, effective and immunogenic vaccine candidate for diarrheagenic Escherichia coli main pathotypes in a mouse model |
| Q46811016 | Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs |
| Q36522053 | Disparate adjuvant properties among three formulations of "alum" |
| Q24599065 | Eating dirt |
| Q34540207 | Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge |
| Q34279064 | Effect of adjuvants on the humoral immune response to congopain in mice and cattle |
| Q33994533 | Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2. |
| Q36293581 | Efficient delivery of antigen to DCs using yeast-derived microparticles |
| Q35634133 | Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer |
| Q42683603 | Efficient induction of comprehensive immune responses to control pathogenic E. coli by clay nano-adjuvant with the moderate size and surface charge |
| Q28749625 | Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice |
| Q42203471 | Enhanced immune responses of foot-and-mouth disease vaccine using new oil/gel adjuvant mixtures in pigs and goats |
| Q28268931 | Enhancing immune responses to inactivated porcine parvovirus oil emulsion vaccine by co-inoculating porcine transfer factor in mice |
| Q42049992 | Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation |
| Q46816112 | Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B. |
| Q40499124 | Evaluation of different chemical adjuvants on an avian influenza H6 DNA vaccine in chickens |
| Q41856768 | Evaluation of sucrose esters as alternative surfactants in microencapsulation of proteins by the solvent evaporation method |
| Q34138616 | Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines |
| Q37135480 | Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties |
| Q83548587 | Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants |
| Q57229596 | Freeing vaccine adjuvants from dangerous immunological dogma |
| Q39187343 | Freeze-thaw stress of Alhydrogel ® alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen |
| Q40959511 | From Stock Bottle to Vaccine: Elucidating the Particle Size Distributions of Aluminum Adjuvants Using Dynamic Light Scattering |
| Q41866408 | Gamma irradiation of active self-healing PLGA microspheres for efficient aqueous encapsulation of vaccine antigens |
| Q42542911 | Genetic fusion of proteins to the SIV Tat protein enhances their immunogenicity |
| Q80207645 | Ginsenoside Rd elicits Th1 and Th2 immune responses to ovalbumin in mice |
| Q34238526 | HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen |
| Q50759965 | Haemolytic activities and adjuvant effect of Astragalus membranaceus saponins (AMS) on the immune responses to ovalbumin in mice. |
| Q42228751 | Highly versatile immunostimulating nanocapsules for specific immune potentiation. |
| Q37034318 | Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide |
| Q27023844 | Hypothesis driven development of new adjuvants: short peptides as immunomodulators |
| Q30388683 | Identification of Adjuvantic Activity of Amphotericin B in a Novel, Multiplexed, Poly-TLR/NLR High-Throughput Screen |
| Q44164380 | Immune response and prophylactic efficacy of smegmosomes in a hamster model of leptospirosis |
| Q41431983 | Immunogenicity and protection of oral influenza vaccines formulated into microparticles |
| Q35193549 | Immunological mechanisms of specific immunotherapy with pollen vaccines: implications for diagnostics and the development of improved vaccination strategies |
| Q50457343 | Immunomodulatory effect of tea saponin in immune T-cells and T-lymphoma cells via regulation of Th1, Th2 immune response and MAPK/ERK2 signaling pathway. |
| Q40084746 | Improving the efficacy of a prophylactic vaccine formulation against lymphatic filariasis |
| Q44165390 | Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant |
| Q47738688 | Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration |
| Q40482585 | Induction of specific humoral immune response in mice immunized with ROP18 nanospheres from Toxoplasma gondii. |
| Q42222109 | Inflammatory responses following intramuscular and subcutaneous immunization with aluminum-adjuvanted or non-adjuvanted vaccines |
| Q85195094 | Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles |
| Q39708894 | Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination. |
| Q38113271 | Intradermal powder immunization with protein-containing vaccines |
| Q34343294 | Intranasal vaccination against plague, tetanus and diphtheria |
| Q27010434 | Japanese encephalitis: the virus and vaccines |
| Q39949693 | Leptosome-entrapped leptospiral antigens conferred significant higher levels of protection than those entrapped with PC-liposomes in a hamster model |
| Q44959008 | Leptospira immunoglobulin-like protein A variable region (LigAvar) incorporated in liposomes and PLGA microspheres produces a robust immune response correlating to protective immunity |
| Q36690859 | Materials that harness and modulate the immune system |
| Q30388672 | Mechanisms of Antigen Adsorption Onto an Aluminum-Hydroxide Adjuvant Evaluated by High-Throughput Screening |
| Q34787679 | Mechanisms of stimulation of the immune response by aluminum adjuvants |
| Q54311492 | Methods to Prepare Aluminum Salt-Adjuvanted Vaccines. |
| Q41006286 | Microfabrication for Drug Delivery |
| Q35192199 | Microparticles as vaccine adjuvants and delivery systems |
| Q36316809 | Microparticles for oral delivery of vaccines |
| Q42862823 | Microparticulate systems for targeted drug delivery to phagocytes |
| Q37642613 | Mucosal vaccines: recent progress in understanding the natural barriers. |
| Q42862259 | Mycobacterial cell-wall skeleton as a universal vaccine vehicle for antigen conjugation. |
| Q33757269 | Myth, menace or medical blessing? The clinical potential and the problems of genetic vaccines |
| Q33834985 | Nanoparticle-allergen complexes for allergen immunotherapy. |
| Q36968297 | Nanoparticles and microparticles as vaccine-delivery systems |
| Q26825418 | Nanoparticulate adjuvants and delivery systems for allergen immunotherapy |
| Q36968305 | New adjuvants: EU regulatory developments |
| Q37838783 | Novel approaches to oral immunization for hepatitis B. |
| Q44439595 | OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242–310 from the circumsporozoite protein of Plasmodium berghei |
| Q57478910 | Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want |
| Q35006422 | PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy |
| Q33306626 | Particle size determination in aluminum hydroxide suspensions using near-infrared transmittance spectroscopy |
| Q36784106 | Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects |
| Q51534139 | Pathogen-Mimicking Polymeric Nanoparticles based on Dopamine Polymerization as Vaccines Adjuvants Induce Robust Humoral and Cellular Immune Responses. |
| Q37860707 | Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines |
| Q37838652 | Peptide/protein vaccine delivery system based on PLGA particles. |
| Q43276080 | Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats |
| Q30355798 | Physiochemical and functional characterization of antigen proteins eluted from aluminum hydroxide adjuvant. |
| Q37349074 | Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells |
| Q40101692 | Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. |
| Q37149102 | Poly(ethylene glycol)-modified proteins: implications for poly(lactide-co-glycolide)-based microsphere delivery. |
| Q36447615 | Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines |
| Q37010485 | Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. |
| Q37684900 | Polymer blend particles with defined compositions for targeting antigen to both class I and II antigen presentation pathways |
| Q33359620 | Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine |
| Q45098418 | Preparation and characterization of nickel nanoparticles for binding to his-tag proteins and antigens |
| Q36944222 | Preparation of recombinant vaccines. |
| Q37969516 | Production and characterization of peptide antibodies. |
| Q35709192 | Programming the composition of polymer blend particles for controlled immunity towards individual protein antigens |
| Q37810816 | Progress towards a needle-free hepatitis B vaccine |
| Q37259642 | Promising particle-based vaccines in cancer therapy. |
| Q58827812 | Protective anti-mycobacterial T cell responses through exquisitein vivo activation of vaccine-targeted dendritic cells |
| Q35963399 | Protective effect of recombinant staphylococcal enterotoxin A entrapped in polylactic-co-glycolic acid microspheres against Staphylococcus aureus infection |
| Q28846409 | Protective immunity against toxoplasmosis in mice induced by single-dose immunization with rSAG1/2 protein released from poly(lactide-co-glycolide) microparticles |
| Q33912121 | Protein coated microcrystals formulated with model antigens and modified with calcium phosphate exhibit enhanced phagocytosis and immunogenicity |
| Q81690459 | PyNTTTTGT prototype oligonucleotide IMT504 is a potent adjuvant for the recombinant hepatitis B vaccine that enhances the Th1 response |
| Q46594886 | Reactogenicity and safety assessment of an attenuated nanovaccine against scorpion envenomation: Preclinical study |
| Q37719553 | Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers |
| Q34756188 | Recent advances in vaccine adjuvants |
| Q35143257 | Recent advances in veterinary vaccine adjuvants |
| Q34376294 | Recent developments in adjuvants for vaccines against infectious diseases |
| Q38068954 | Recent progress towards development of a Shigella vaccine |
| Q46663461 | Relationship between haemolytic and adjuvant activity and structure of protopanaxadiol-type saponins from the roots of Panax notoginseng |
| Q30405708 | Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. |
| Q82483005 | Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines |
| Q64881146 | Self-healing encapsulation and controlled release of vaccine antigens from PLGA microparticles delivered by microneedle patches. |
| Q47123344 | Sequestering of damage-associated molecular patterns (DAMPs): a possible mechanism affecting the immune-stimulating properties of aluminium adjuvants |
| Q30386156 | Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice. |
| Q37743456 | Simultaneous enhancement of cellular and humoral immunity by the high salt formulation of Al(OH)3 adjuvant |
| Q33728320 | Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. |
| Q46608381 | Species-dependent role of type I IFNs and IL-12 in the CTL response induced by humanized CpG complexed with β-glucan |
| Q81390492 | Spectroscopic characterization of antibodies adsorbed to aluminium adjuvants: correlation with antibody vaccine immunogenicity |
| Q34722666 | Stabilization of tetanus toxoid encapsulated in PLGA microspheres |
| Q36316814 | Starch microparticles as vaccine adjuvant |
| Q57142625 | Structural Characterization and Formulation Development of a Trivalent Equine Encephalitis Virus-Like Particle Vaccine Candidate |
| Q33800766 | Structure-based programming of lymph-node targeting in molecular vaccines |
| Q40130682 | Structure-function relationships of protein-lipopeptide complexes and influence on immunogenicity |
| Q37379662 | Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination |
| Q51415073 | Syntheses of Human TLR8-Specific Small-Molecule Agonists. |
| Q38072067 | Synthetic adjuvants for vaccine formulations: phytol derivatives |
| Q28387541 | Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts |
| Q35177573 | T cell immunostimulation by methyl inosine 5'-monophosphate: application to infectious diseases |
| Q40549969 | The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability |
| Q57609134 | The extradomain A of fibronectin (EDA) combined with poly(I:C) enhances the immune response to HIV-1 p24 protein and the protection against recombinant Listeria monocytogenes-Gag infection in the mouse model |
| Q37956385 | The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant |
| Q38453147 | The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm. |
| Q52015425 | The mouse immune response to carrier erythrocyte entrapped antigens. |
| Q46018304 | The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. |
| Q45026767 | The structure of HBsAg particles is not modified upon their adsorption on aluminium hydroxide gel. |
| Q40044140 | Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future |
| Q38317118 | Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy |
| Q38214121 | Toll-like receptor-based adjuvants: enhancing the immune response to vaccines against infectious diseases of chicken |
| Q38404208 | Toward a Single-Dose Vaccination Strategy with Self-Encapsulating PLGA Microspheres |
| Q37036694 | Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles |
| Q47764736 | Ultrafine carbon black particles cause early airway inflammation and have adjuvant activity in a mouse allergic airway disease model |
| Q43784039 | Ultraviolet light and resistance to infectious diseases |
| Q34857878 | Ultraviolet radiation, resistance to infectious diseases, and vaccination responses |
| Q37366748 | Use of o-phthalaldehyde assay to determine protein contents of Alhydrogel-based vaccines |
| Q34517903 | Vaccination of mice with an antigenic serine protease-like protein elicits a protective immune response against Trichinella spiralis infection. |
| Q46516149 | Vaccination with the recombinant allergen ProDer p 1 complexed with the cationic lipid DiC14-amidine prevents allergic responses to house dust mite |
| Q91705195 | Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity |
| Q50063256 | Vaccine adjuvants: smart components to boost the immune system |
| Q35791765 | Vaccines for conformational disorders |
| Q21284959 | Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development |
| Q53771539 | Venom conjugated polylactide applied as biocompatible material for passive and active immunotherapy against scorpion envenomation. |
| Q35033443 | Vibrio cholerae ghosts (VCG) exert immunomodulatory effect on dendritic cells for enhanced antigen presentation and induction of protective immunity |
| Q38105343 | Viral vaccines for bony fish: past, present and future. |
| Q35192175 | Virosomal adjuvanted antigen delivery systems |
| Q37668409 | Working together: interactions between vaccine antigens and adjuvants |
| Q32175658 | Yeast lysates carrying the nucleoprotein from measles virus vaccine as a novel subunit vaccine platform to deliver Plasmodium circumsporozoite antigen |
Search more.